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Background: Polymorphonuclear neutrophils, stimulated by the activated complement factor C5a, have been
implicated in cardiac ischemia/reperfusion injury. ADC-1004 is a competitive C5a receptor antagonist that has been
shown to inhibit complement related neutrophil activation. ADC-1004 shields the neutrophils from C5a activation
before they enter the reperfused area, which could be a mechanistic advantage compared to previous C5a
directed reperfusion therapies. We investigated if treatment with ADC-1004, according to a clinically applicable
protocol, would reduce infarct size and microvascular obstruction in a large animal myocardial infarct model.
Methods: In anesthetized pigs (42-53 kg), a percutaneous coronary intervention balloon was inflated in the left
anterior descending artery for 40 minutes, followed by 4 hours of reperfusion. Twenty minutes after balloon
inflation the pigs were randomized to an intravenous bolus administration of ADC-1004 (175 mg, n = 8) or saline
(9 mg/ml, n = 8). Area at risk (AAR) was evaluated by ex vivo SPECT. Infarct size and microvascular obstruction
were evaluated by ex vivo MRI. The observers were blinded to the treatment at randomization and analysis.
Results: ADC-1004 treatment reduced infarct size by 21% (ADC-1004: 58.3 ± 3.4 vs control: 74.1 ± 2.9%AAR,
p = 0.007). Microvascular obstruction was similar between the groups (ADC-1004: 2.2 ± 1.2 vs control: 5.3 ± 2.5%
AAR, p = 0.23). The mean plasma concentration of ADC-1004 was 83 ± 8 nM at sacrifice. There were no significant
differences between the groups with respect to heart rate, mean arterial pressure, cardiac output and blood-gas
data.
Conclusions: ADC-1004 treatment reduces myocardial ischemia-reperfusion injury and represents a novel
treatment strategy of myocardial infarct with potential clinical applicability.
Background
Reperfusion therapy is the standard treatment of acute
myocardial infarction, and restoration of blood flow lim-
its infarct size and reduces mortality. Paradoxically,
reperfusion in itself may also cause additional damage to
the previously ischemic myocardium, a phenomenon
referred to as reperfusion injury [1-3]. The molecular
basis for reperfusion injury has not been fully elucidated,
but there is evidence for several possible mechanisms of
damage including oxidative stress, calcium overload,
mitochondrial damage, apoptosis, complement activation
and an inflammatory reaction. One aspect of reperfusion
injury is the impairment of microvascular coronary blood
flow (microvascular obstruction) seen during reperfusion.
The development of microvascular obstruction is a mul-
tifactorial process attributable to endothelial damage,
thrombus formation, neutrophil aggregation, myocyte
swelling, capillary spasm and debris from dying cells
[4,5]. Microvascular obstruction has been found to be a
strong independent predictive marker of postinfarction
complications even after adjustment for infarct size [6].
Complement activation is an early event in cardiac
ischemia-reperfusion injury [7], and the activated com-
plement system can induce tissue damage both directly
and in-directly [8-10]. Directly, the C5b-9 membrane
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shown to induce myocardial injury [11,12]. Complement
cascade products also appear to injure the endothelium
leading to a vicious circle of vasoconstriction, microvas-
cular hypoperfusion and apoptosis [13,14]. Indirectly,
the activated complement factor C5a stimulates neutro-
phils by inducing chemotactic migration [15], aggrega-
tion [16,17], and release of cytotoxic products such as
proteases, elastases and reactive oxygen species that
destroy the cell membrane and cause cell death [16-18].
Neutrophils activated by C5a may also contribute to
microvascular obstruction by plugging of the microcir-
culation [19]. Further support for the importance of
neutrophils in ischemia-reperfusion injury is offered by
studies demonstrating a cardioprotective effect of either
depletion of circulating neutrophils or by inhibition of
neutrophil function [17,18]. For these reasons, neutro-
phils are thought to be important mediators of cardiac
ischemia-reperfusion injury [20].
ADC-1004 is a truncated and mutated form of the
Chemotaxis inhibitory protein of Staphylococus aureus
(CHIPS) [21-23]. It was developed using FIND®, a direc-
ted in-vitro evolution technology that mimics the natural
process of creating protein diversity through recombina-
tion [21]. ADC-1004 binds to, but does not activate, the
C5a receptor, thereby acting as an effective antagonist
[24]. By intervening directly at the C5a receptor, it offers
the advantage of exerting its effect on circulating neutro-
phils, prior to the arrival of the neutrophils at the infarct
area. This could be a key to effective anti-neutrophil
treatment of myocardial ischemia-reperfusion injury.
We investigated if treatment with ADC1004, accord-
ing to a clinically applicable protocol, would reduce
myocardial injury in a large animal ischemia/reperfusion
model. The primary- and secondary end points were
reductions of infarct size and microvascular obstruction
relative to the area at risk.
Methods
Experimental preparation
Healthy domestic male and female juvenile pigs weighing
42-53 kg were fasted overnight with free access to water.
The animals were premedicated with Ketaminol (Keta-
mine, Intervet, Danderyd, Sweden), 100 mg/ml, 0.15 ml/
kg, and Rompun (Xylazin, Bayer AG, Leverkusen, Ger-
many), 20 mg/ml, 0.1 ml/kg intramuscularly 30 min
before the procedure. After induction of anesthesia with
thiopental 12.5 mg/kg (Pentothal, Abbott, Stockholm,
Sweden) the animals were orally intubated with cuffed
endotracheal tubes. A slow infusion of 1 μl/ml fentanyl
(Fentanyl, Pharmalink AB, Stockholm, Sweden) in buf-
fered glucose (25 mg/ml) was started at a rate of 2 ml/
min and adjusted if needed. During balanced anaesthesia
thiopental (Pentothal, Abbott, Stockholm, Sweden), was
titrated towards animal requirements with small bolus
doses. Mechanical ventilation was established with a Sie-
mens-Elema 900B ventilator in a volume-controlled
mode, adjusted in order to obtain normocapnia (pCO2:
5.0-6.0 kPa). The animals were ventilated with a mixture
of nitrous oxide (70%) and oxygen (30%). The pigs were
continuously monitored by electrocardiography (ECG).
Arterial blood pressure was measured using an
MLT0380/D blood pressure transducer (ADInstruments
Inc, Colorado Springs, CO, USA). Heparin (200 IU/kg)
was given intravenously at the start of the catheterization.
A 12 F introducer sheath (Boston Scientific Scimed,
Maple Grove, MN, USA) was inserted into the surgically
exposed left femoral vein. A 0.021-inch guide wire (Safe-
T-J Curved™, Cook Medical Inc, Bloomington, IN, USA)
was inserted into the proximal inferior vena cava through
the introducer. Using the guide wire, a 10.7 F Celsius
Control™ catheter (Innercool Therapies Inc, San Diego,
CA, USA) was placed into the inferior vena cava with the
tip of the catheter at the level of the diaphragm. Body
temperature was measured with a temperature probe
(TYCO Healthcare Norden AB, Solna, Sweden) placed in
the distal part of the esophagus. The catheter and the
temperature probe were connected to the Celsius Con-
trol and the system was set to maintain a normal pig
body temperature of 38.0°C. A 6 F introducer sheath
(Boston Scientific Scimed, Maple Grove, MN, USA) was
inserted into the surgically exposed left carotid artery
upon which a 6 F FL4 Wiseguide™ (Boston Scientific
Scimed, Maple Grove, MN, USA) was inserted into the
left main coronary artery. The catheter was used to place
a 0.014-inch PT Choice™ guide wire (Boston Scientific
Scimed, Maple Grove, MN, USA) into the distal portion
of the LAD. A 3.0-3.5 × 15 mm Maverick monorail™
angioplasty balloon (Boston Scientific Scimed, Maple
Grove, MN, USA) was then positioned in the mid portion
of the LAD, immediately distal to the first diagonal
branch. A 9 F introducer sheath (Boston Scientific
Scimed, Maple Grove, MN, USA) was inserted into the
surgically exposed right jugular vein. A 7.5 F CCOmbo™
continuous cardiac output pulmonary artery catheter
(Edwards Lifesciences, Irvine, CA, USA) was inserted
into a pulmonary artery. Cardiac output was continu-
ously recorded using a Vigilance™ monitor (Edwards Life-
s c i e n c e s ,I r v i n e ,C A ,U S A ) .T h em o n i t o ru s e st h e r m a l
energy emitted by the thermal filament located on the
catheter to calculate cardiac output using thermodilution
principles. All radiological procedures were performed
using an Opescope Pleno™ imaging system (Shimadzu
Corp., Kyoto, Japan).
Experimental protocol
Ischemia was induced by inflation of the angioplasty bal-
loon for 40 minutes. An angiogram was performed after
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loon in order to verify total occlusion of the coronary
vessel and correct balloon positioning. After deflation of
the balloon a subsequent angiogram was performed to
verify restoration of blood flow in the previously
occluded artery. Twenty minutes before balloon deflation
and reperfusion the animals were randomized to treat-
ment with an intravenous bolus dose of ADC-1004 (175
mg, n = 8) or saline (0.9 mg/ml, n = 8). The observers
were blinded to the treatment at randomization and ana-
lysis. The hearts were explanted four hours after reperfu-
sion and analyzed ex vivo by SPECT and MRI for infarct
size, microvascular obstruction and area at risk.
To monitor the plasma concentration of ADC-1004,
plasma samples were collected five minutes after admin-
istration, at reperfusion, and one, two, three and four
hours after reperfusion. Blood levels of leukocytes were
measured at baseline and at sacrifice. Plasma levels of
Troponin T were analyzed at baseline and at two, three
and four hours after reperfusion. Arterial blood-gases
were analyzed at baseline, at reperfusion and one hour
after reperfusion. Mean arterial blood pressure, heart
rate and cardiac output was measured continuously
until one hour after reperfusion.
Dose prediction
Prior to the in-vivo experiment, the potency of ADC-
1004 to the C5a receptor was estimated in an in-vitro
assay where C5a-induced calcium mobilization was stu-
died by flow cytometry [24]. Pig neutrophils were used
and the ability of ADC-1004 to shift C5a-induced con-
centration-response curves was analysed by Schild-plots,
yielding a potency estimate pA2 of 29 nM for ADC-
1004 to pig neutrophils. It has been reported that clini-
cally effective concentrations correlates closely with the
concentration required for 75% receptor occupancy cal-
culated from the in vitro potency [25], which in the case
of ADC-1004, would give an estimated effective concen-
tration of about 90 nM. Thus, the aim was to give a
dose that kept the plasma concentration at or above 90
nM throughout the experiment.
Imaging
Ex vivo imaging of the heart was undertaken according
to a previously described protocol [26,27]. The MR and
SPECT images were analyzed using freely available soft-
ware (Segment v1.700, Medviso, Lund, Sweden, http://
segment.heiberg.se) [28,29].
Infarct size and microvascular obstruction assessed by ex
vivo MRI
A gadolinium-based contrast agent (Dotarem, gadoteric
acid, Gothia Medical AB, Billdal, Sweden) was adminis-
tered intravenously (0.4 mmol/kg) 30 minutes prior to
explantation of the heart. The heart was explanted 4
hours after initiation of reperfusion. After explantation,
the heart was immediately rinsed in cold saline and the
ventricles were filled with balloons containing deuter-
ated water. MRI was performed using a 1.5 T MR scan-
ner (Intera, Philips, Best, the Netherlands). T1-weighted
images (repetition time = 20 ms, echo time = 3.2 ms,
flip angle = 70° and 2 averages) with an isotropic resolu-
tion of 0.5 mm covering the entire heart were then
acquired using a quadrature head coil. Approximately
200 short-axis images were generated of each heart,
yielding a high resolution for infarct size delineation.
The endocardial and epicardial borders of the left
ventricular myocardium were manually delineated in
short-axis images. The volume of the left ventricular
myocardium was calculated as the product of the slice
thickness (cm) and the area formed by the delineated
borders of the epi- and endocardium. The infarct size
was determined as the volume of infarcted myocardium
(cm
3). The infarct volume was calculated as the product
of the slice thickness (cm) and the area of hyperen-
hanced pixels (cm
2) with a signal intensity above the
infarction threshold, defined as >8 SD above the mean
intensity of non-affected remote myocardium. Microvas-
cular obstruction was defined as hypointense regions in
the core of the infarction which had signal intensity less
than the threshold for infarction. The size of the infarct
and microvascular obstruction was expressed as percent
of the area at risk (AAR), in order to adjust for any dif-
ferences in AAR.
Assessment of area at risk by ex vivo SPECT
Single photon emission computed tomography
(SPECT) was used to assess the AAR as percent of left
ventricular myocardium (LVM). 1000 MBq of
99 mTc-
tetrofosmin were administered intravenously 10 min-
utes before deflation of the angioplasty balloon. Ex
vivo imaging was performed with a dual head camera
(Skylight, Philips, Best, the Netherlands) at 64 projec-
tions (60 s per projection) with a 64 × 64 matrix and a
zoom factor of 2.19, yielding a digital resolution of
4.24 × 4.24 × 4.24 mm. Iterative reconstruction using
maximum likelihood-expectation maximization
(MLEM) was performed with a low-resolution Butter-
worth filter with a cut-off frequency set to 0.6 of
Nyquist and order 5.0. No attenuation or scatter cor-
rection was applied. Finally short and long-axis images
were reconstructed. The endocardial and epicardial
borders of the left ventricle that were manually deli-
neated in the MR images were copied to the co-regis-
tered SPECT images. A SPECT defect was defined as a
region within the MRI-determined myocardium with
counts lower than 55% of the maximum counts in the
myocardium [30].
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Plasma levels of Troponin T were analysed using the
Elecsys immunoassay system (Roche Diagnostics Scandi-
navia, Bromma, Sweden). The white blood cell count
(WBC) was measured using a Sysmex XE-5000 auto-
mated hematology analyzer (Sysmex Corporation, Kobe,
Japan). Blood-gases were analyzed in an automated
bench top analyzer (Radiometer Medical ApS, Brønshøj,
Denmark). Plasma levels of ADC-1004 were analysed by
an ELISA method. In this ELISA, the plates were coated
with 2 μg/ml of a mouse mab against ADC-1004. The
plates were washed and blocked (3% milkpowder in PBS
0.05% Tween 20) and then incubated with plasma sam-
ples. ADC-1004 was detected with 3 μg/ml polyclonal
rabbit anti-CHIPS N-terminal IgG (IgG produced by
immunization of a rabbit with a KLH-coupled synthetic
peptide corresponding to CHIPS N-terminal amino
acids 1-14) and horseradish peroxidase (HRP) conju-
gated goat anti-rabbit IgG (Southern Biotech, Birming-
ham, AL, USA).
Ethics
The study conforms to the Guide for the Care and Use
of Laboratory Animals, US National Institute of Health
(NIH Publication No. 85-23, revised 1996) and was
approved by the local animal research ethics committee.
Calculation and statistics
Calculations and statistics were performed using the
GraphPad Prism 5.0 software (GraphPad Software Inc.,
La Jolla, CA, USA). Values are presented as mean ±
SEM. Statistical significance was accepted when p < 0.05
(Mann-Whitney test, two-tailed).
Results
A total of 20 animals were used. Of those, one was not
included due to an anomalous coronary anatomy and
one died in ventricular fibrillation prior to randomiza-
tion. Therefore, 18 animals were randomized between
control and ADC-1004. One animal in each group died
from pulseless electrical activity. Thus, eight animals in
each group were included in the final comparison
between ADC-1004 and control. All animals in the
treatment group experienced ventricular fibrillation
(VF) or pulseless ventricular tachycardia (VT). Six of
eight animals in the control group experienced VT/VF.
All of these were successfully defibrillated to sinus
rhythm and spontaneous circulation. Two animals that
received ADC-1004 experienced a transient fall in
blood pressure immediately after administration of the
drug. This did not occur when the administration was
carried out over a period of 1.5-3 minutes. No differ-
ences were observed between the ADC-1004 group
and the control group with respect to the time from
reperfusion to explantation (ADC-1004: 286 ± 2 vs
control: 290 ± 4 min, NS).
Imaging and hemodynamic parameters
ADC-1004 treatment significantly reduced the primary
end-point, infarct size relative to the area at risk, by 21%
(ADC-1004: 58.3 ± 3.4 vs control: 74.1 ± 2.9%AAR, p =
0.007) (Figure 1A). Infarct size unadjusted for differ-
ences in area at risk was also reduced in the ADC-1004
group, although it did not reach statistical significance
(ADC-1004: 23.0 ± 3.0 vs control: 27.1 ± 1.4%LVM, p =
0 . 1 6 )( F i g u r e2 ) .T h ea r e aa tr i s kw a ss i m i l a rb e t w e e n
the groups (ADC-1004: 38.9 ± 3.7 vs control: 37.1 ±
Figure 1 Imaging.( A) ADC-1004 causes a relative reduction in infarct size of 21%, p = 0.007. (B) Microvascular obstruction was similar between
the groups, p = 0.23. Horizontal lines denote mean. For microvascular obstruction, the median value was 2.3 percent in the control group and
0.8 percent in the ADC-1004 group.
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was similar between the groups (ADC-1004: 2.2 ± 1.2 vs
control: 5.3 ± 2.5%AAR, p = 0.23) (Figure 1B). A large
variation in microvascular obstruction was observed in
both groups. There were no significant differences in
hemodynamic parameters between the groups at base-
line, at randomization or onwards (Figure 3).
Blood sample analysis
Mirroring unadjusted infarct size, the area under the
curve (AUC) for Troponin T release was insignificantly
reduced by 21% in the ADC-1004 group (ADC-1004:
2823 ± 528 vs control: 3566 ± 615, p = 0.38). The Tro-
ponin T detection range was 0.03 - 24 μg/l and in the
control group the values were higher than the upper
detection limit on a large number of occasions (ADC-
1004: 3 vs control: 10 occasions).
The mean plasma concentration of ADC-1004 at
explantation was 83 ± 8 nM (Figure 4). The degree of
reactive leukocytosis in peripheral venous blood were
similar between treatment and control at sacrifice
(ADC-1004: 149.5 ± 12.1 vs control: 156.5 ± 15.0 per-
cent of baseline value, NS). Blood-gases were similar
between the groups (Table 1).
Figure 2 Infarct size. Delayed contrast enhanced MR images from one typical animal from each group. Approximately 200 short-axis images,
each 0.5 mm thick, are analyzed from every heart. Infarcted myocardium (white) is defined as hyper-enhanced myocardium with signal intensity
above eight standard deviations of the signal intensity in the remote myocardium. Microvascular obstruction is defined as hypointense regions
in the core of the infarction with signal intensity less than the threshold for infarction.
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Page 5 of 9Figure 3 Hemodynamic parameters. There were no statistically significant differences in (A) cardiac output, (B) heart rate or (C) mean arterial
pressure at baseline, at randomization or onwards. The dashed line marks the onset of reperfusion. Error-bars denote SEM.
Figure 4 Plasma concentration of ADC-1004.( A) Plasma concentration over the entire experimental period. ADC-1004 was administered 20
minutes prior to reperfusion, marked by the dashed line. (B) Plasma concentration at sacrifice. The dashed line marks the desired level of
ADC1004, a concentration that blocks 75% of the C5a receptors on the neutrophils. This level of blockage is considered to be therapeutic.
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This study evaluated the cardioprotective effect of ADC-
1004 treatment, according to a clinically applicable pro-
tocol for ST-segment elevation myocardial infarction
(STEMI) with administration before reperfusion. Treat-
ment with ADC-1004 was found to significantly reduce
infarct size by 21% without any hemodynamic side
effects.
The porcine model was chosen because it is a large
animal model that resembles the human pathophysiol-
ogy more closely than rodent models, and also allows
for a closed chest model utilising human coronary inter-
ventional devices. A percutaneous catheter-based
approach allows for induction of ischemia with mini-
mum trauma, operation-induced stress and secondary
changes in circulatory physiology. The porcine model
also offers a possibility of SPECT and MRI for ischemia
and infarct size evaluation. Ex vivo MRI allows for
achievement of high resolution images of the myocardial
infarction and correlates closely to histology [27,31].
MRI and SPECT are also the gold standard methods of
evaluation of ischemia and infarct size in clinical prac-
tice. Temperature is known to be a major determinant
of infarct size [32]. In order to eliminate spontaneous
hypothermia as a confounding factor for infarct size
development, a normal core body temperature of pigs
(38°C) was maintained. The total ischemia time of 40
min is shorter than in the typical patient with myocar-
dial infarction, which often experience 2-4 hours of
ischemia before start of treatment. However, pig infarct
progress has been shown to be approximately 7 times
more rapid than human [33], suggesting that the current
model represents a human STEMI with approximately
five hours duration. The faster infarct development seen
in pigs is likely due to the lack of collaterals in the por-
cine coronary circulation.
Treatment with ADC-1004 caused a statistically signif-
icant reduction in infarct size of 21%. The extent of
microvascular obstruction was similar between the
groups, suggesting that the relative contribution of acti-
vated neutrophils to the development of microvascular
obstruction is less than the contribution of neutrophils
to infarct development. The degree of reactive leukocy-
tosis was comparable between the groups, which was to
be expected. It is likely that the leukocytes were mobi-
lized during catheterization and early ischemia, prior to
administration of ADC-1004. As the mean plasma con-
centration of ADC-1004 at sacrifice was found to be 83
nM, the aim to keep the plasma concentration at a ther-
apeutic level (i.e. at or above 90 nM) was met for the
major part of reperfusion [25]. Thus, as shown in the
dose prediction experiment described in the methods
section, the circulating neutrophils were blocked at the
C5a receptor in the ADC-1004 group and rendered
resistant to C5a related activation. The activation has
been shown to peak two hours after reperfusion and to
rapidly decline thereafter [34]. C5a has also been shown
to have a short half-life, with effects resolving within a
few minutes [35]. Consequently, a bolus administration
of ADC-1004 prior to reperfusion seems to cover the
entire therapeutic window for inhibition of C5a-related
neutrophil activation. A major advantage with ADC-
1004 is that, if it is administered before reperfusion, it
will protect the circulating neutrophils before they reach
the ischemic zone, thereby avoiding even a brief period
of activation. There were no significant differences in
hemodynamic parameters between the groups, suggest-
ing that ADC-1004 is safe for administration in patients
with acute myocardial infarction.
Several other preclinical studies have evaluated the
effect of blocking the C5a component, either by block-
ing the conversion of C5 to C5a, by neutralising antibo-
dies to C5a or by antagonists of the C5a receptor, over
all with findings of cardioprotective effects in animal
models [36-39]. Exposure of C5a at a sublytic dose prior
to ischemia has also been shown to induce cardioprotec-
tion [40], possibly by triggering a preconditioning effect.
The preclinical evidence by large, clearly supports a
therapeutic possibility in inhibiting C5a related neutro-
phil activation, which is also in line with the findings in
this study.
A few substances have been clinically evaluated
recently. The FIRE trial evaluated the effect of inhibition
o ft h en e u t r o p h i l so ni n f a r c ts i z eb yF X 0 6 ,aV E - c a d -
herin inhibitor, with the finding of a 58% reduction in
necrotic core zone after five days [41]. However, this
finding did not remain after four months [41]. The
APEX AMI trial evaluated the humanized monoclonal
antibody pexelizumab, that binds the C5 component of
complement, as an adjunct to PCI in improving 30-day
mortality from STEMI [42]. In this trial, mortality was
unaffected by pexelizumab treatment. Furthermore, even
though pexelizumab had been shown to reduce apopto-
sis and leukocyte infiltration resulting in reduced myo-
cardial injury in an animal model [39,43], pexelizumab
treatment initiated prior to reperfusion failed to
Table 1 Arterial blood-gas data
Control ADC-1004 P-value
pH - baseline 7.48 (± 0.02) 7.49 (± 0.03) NS
pH - 40 min 7.36 (± 0.06) 7.41 (±0.03) NS
pH - 100 min 7.42 (±0.02) 7.43 (±0.03) NS
Base excess - baseline 4.06 (±1.48) 5.15 (±0.99) NS
Base excess - 40 min -1.25 (±3.07) 2.85 (±1.16) NS
Base excess - 100 min 1.05 (±1.38) 3.25 (±1.10) NS
Values are expressed as mean and SEM. pH and base excess were similar
between the groups throughout the experiment. The unit for base excess is
mmol/L and for pH -log10{H
+}.
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However, an antibody to C5 can neither inhibit the C5a
that has already been generated nor can it exert its
effect prior to the arrival of the substance in the infarct
area. A C5a receptor antagonist, on the other hand,
offers the advantage of blocking the receptor on the
neutrophils prior to the arrival of the neutrophil in the
infarct area.
The C5a receptor is also found on cardiomyocytes,
and this receptor activates an intracellular signalling cas-
cade involving protein kinase C isoenzyme delta (PKC-δ)
that may contribute to ischemia/reperfusion injury [45].
The substance KAI-9803 is a PKC-δ inhibitor that has
been shown to reduce myocardial injury in animal mod-
els [46,47], and is now in clinical development [48].
Effects of ADC-1004 on cardiomyocytes could mediate
some of the cardioprotective effect by reducing PKC-δ
activation, but this needs to be confirmed in future
experiments.
Conclusions
In summary, ADC-1004 treatment, according to a clini-
cally applicable protocol, reduces myocardial ischemia-
reperfusion injury. ADC-1004 thus represents a novel
treatment strategy of myocardial ischemia-reperfusion
injury with potential clinical applicability.
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